尿酸与糖尿病肾病风险
Uric acid and risk of diabetic kidney disease.
作者信息
Mauer Michael, Doria Alessandro
机构信息
Department of Pediatrics and Medicine, University of Minnesota School of Medicine, 515 Delaware St SE, Room 13-271 Moos Tower, Minneapolis, MN, 55455, USA.
Research Division, Section on Genetics and Epidemiology, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, One Joslin Place, Boston, MA, 02215, USA.
出版信息
J Nephrol. 2020 Oct;33(5):995-999. doi: 10.1007/s40620-020-00796-z. Epub 2020 Jul 10.
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) in the Western world. Better control of glycemia and blood pressure, including renin-angiotensin system blockade (RASB), appear to have slowed DKD progression rate but have been unable to substantially decrease the annual incidence of new cases of DKD related ESKD. Thus, new treatment targets are needed. Higher levels of serum uric acid (SUA) have been associated with increased risk and progression of DKD in persons with types 1 (T1D) and 2 (T2D) diabetes and of chronic kidney disease (CKD) in general. This review presents the epidemiological, clinical, and clinical trial evidence regarding the hypothesis that SUA reduction could slow progression of DKD and/or CKD in general.
糖尿病肾病（DKD）是西方世界终末期肾病（ESKD）的主要病因。更好地控制血糖和血压，包括肾素-血管紧张素系统阻断（RASB），似乎减缓了DKD的进展速度，但未能大幅降低与DKD相关的ESKD新病例的年发病率。因此，需要新的治疗靶点。较高水平的血清尿酸（SUA）与1型（T1D）和2型（T2D）糖尿病患者的DKD风险增加及进展相关，总体上也与慢性肾脏病（CKD）相关。本综述介绍了关于降低SUA可减缓DKD和/或总体CKD进展这一假说的流行病学、临床和临床试验证据。
Zotero 插件